SEATTLE, Nov. 29, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial
media network dedicated to the North American cannabis industry, announces publication of an article discussing a key problem
facing the medical cannabis industry: dosing and consistency. Unlike pharmaceuticals, medical cannabis is typically prescribed in a
smokable form that can produce inconsistent effects between patients. Many pharmaceuticals also offer extended release and features
that can make the medicine more efficacious.
The global cannabis industry is projected to reach $146.4 billion by 2025, according to Grand View Research, representing a blistering 34.6 percent compound annual growth rate. With
medical and adult-use legalization across a growing number of countries, there’s an enormous opportunity for innovative companies
to become established market leaders and patients to access new life-changing medications.
Canntab Therapeutics Ltd. (CSE: PILL) (FSE: TBF1) is an emerging leader in solid oral
dosage cannabis formulations, which are designed to make cannabinoid dosing more accurate and reliable, for physicians and their
patients benefit. Investors may want to take a closer look at the company given its robust product portfolio and growing
distribution network.
Strong Product Portfolio
Canntab has made tremendous progress building an intellectual property portfolio with 13 patents pending in the United States
and Canada related to its formulations of cannabis tablets, including instant release, extended release, flash melt, and bi-layer
products available in 2.5mg, 5mg, and 10mg tablets. These products will address a key shortcoming in cannabis-based medications—a
lack of precise, dose-controlled formats supported by pharmacokinetic, dosing, and clinical data to ensure safety and efficacy.
Last year, the company announced an exclusive agreement with Emblem Corp. to develop cannabis-based oral
sustained release formulations. The partnership received Health Canada’s approval for research and development activities, and dissolution testing
showed that the extended release tablets delivered cannabinoids consistently over a 12-hour period. The team plans to file dossiers
with regulatory agencies around the world.
In addition to these agreements, Health Canada recently approved the company’s 420 Therapeutics brand of cannabis wellness
capsules that are made from purified organic hemp seed oil. These capsules are an easy and convenient way to realize the health
benefits of hemp oil, while setting the stage for the company’s long-term goal of manufacturing full spectrum hemp-derived
cannabidiol (CBD) oil.
Joint Venture Distribution
Canntab has signed a number of joint venture agreements around the world to distribute its products to patients across many
jurisdictions.
The company announced a non-binding letter of intent with NewCanna SAS of Bogota, Colombia to
establish a significant bilateral relationship for the sale and distribution of its products. Under the agreement, NewCanna will
distribute products across Colombia, Chile, Paraguay, and Spain in exchange for a one-time, non-refundable license fee of $2
million payable to Canntab after the agreement is finalized.
More recently, the company announced a non-binding letter of intent with Labsco Promedic SA of Monterrey,
Mexico to establish a new distribution channel in Mexico. Under the terms of the agreement, the companies will work together to
formalize a joint venture before the end of the year and launch products within the next five years. Mexico could become a
significant market given the government’s recent liberalization of cannabis laws.
Looking Ahead
Canntab Therapeutics Ltd. (CSE: PILL) (FSE: TBF1) is rapidly approaching commercialization
with new distribution channels in place. In addition, the company recently filed an application to become a licensed producer under
Health Canada’s ACMPR program. If approved, the new designation would enable the company to manufacture products at its current
production facility with minimal additional capital expenditure as compared to a new purpose-built facility.
With an excellent cap structure and no need for short-term financing, investors may want to take a closer look at the company as
it gears up for commercialization. The potential approval of its tablets and new license from Health Canada could prove to be
significant catalysts, while new joint venture agreements could pave the way to near-term income.
For more information, visit the company’s website at www.canntab.ca.
Please follow the link to read the full article:
http://www.cannabisfn.com/canntab-nears-commercialization-innovative-cannabis-tablets/
About CFN Media
CFN Media (CannabisFN) is the leading agency and financial media network dedicated to the global cannabis industry, helps
companies operating in the space attract investors, capital, and publicity. Since 2013, private and public cannabis companies in
the US and Canada have relied on CFN Media to grow and succeed.
Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany
Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand:https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8
Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your
iPhone: http://www.cannabisfn.com
Disclaimer
CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own
independent legal, tax, and/or investment professionals before making any investment decisions. The information provided
on http://www.cannabisfn.com (the ‘Site’) is either original financial news or paid
advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm
enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other
editorials for advertising such companies. We are not an independent news media provider. We make no warranty or
representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly
and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As
such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted.
CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along
with financial and corporate news.
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create
awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
Frank Lane
206-369-7050
flane@cannabisfn.com